Debevoise Advised Carlyle in Its Investment in Resonetics, Valuing the Company at Approximately $2.25 Billion

December 3, 2021

Debevoise & Plimpton LLP has advised Carlyle (NASDAQ: CG) in its acquisition of a significant interest in medical device contract manufacturer Resonetics, valuing the company at approximately $2.25 billion. For more information, please read the press release.

Founded in 1987 and headquartered in Nashua, New Hampshire, Resonetics is a leading provider of micro-manufacturing for innovative medical devices in high-growth therapeutic areas and end markets.

The Debevoise team was led by M&A partners Spencer Gilbert and Kevin Rinker and included partner Jennifer Chu, counsel Kim Le, Keith Slattery and Molly Stockley and associates Yean Do, Hannah Levine, Guy Polani and Vishaal Sharma, finance partner Jeffrey Ross and associate Alexandra Grossman, benefits counsel Kathleen Emberger and associate Spencer Mizerak, tax partner Peter Furci and associate Jay Evans, FDA regulatory partner Paul Rubin and associate Melissa Runsten, capital markets associate Benjamin Pedersen, intellectual property counsel Caroline Geiger and associate Emily MacKay, litigation counsel Jacob Stahl and associate Adam Aukland-Peck and environmental counsel Stuart Hammer.